{"filing":{"accession_number":"0001193125-26-237908","cik":"0001991792","ticker":"CGON","company_name":"CG Oncology, Inc.","form":"8-K","filing_date":"2026-05-26","report_date":null,"primary_document":"ck0001991792-20260520.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1991792/000119312526237908/ck0001991792-20260520.htm"},"events":[{"id":398,"run_id":345,"accession_number":"0001193125-26-237908","anchor_item_number":"5.02","event_type":"exec_departure","event_domain":"governance","is_material":true,"confidence":0.75,"summary":"The filing discloses the separation of Ambaw Bellete, President \u0026 Chief Operating Officer, effective June 30, 2026. While the section also mentions Arthur Kuan's appointment as President, the primary focus and substantive disclosure centers on Bellete's departure and associated severance benefits under his employment agreement. The departure of a C-suite officer (President \u0026 COO) is material to investors.","company_name":"CG Oncology, Inc.","ticker":"CGON","filing_date":"2026-05-26","items":[{"id":1482,"accession_number":"0001193125-26-237908","item_number":"5.02","item_title":"Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.","event_type":"exec_departure","event_domain":"governance","is_material":true,"confidence":0.75,"reasoning":"The filing discloses the separation of Ambaw Bellete, President \u0026 Chief Operating Officer, effective June 30, 2026. While the section also mentions Arthur Kuan's appointment as President, the primary focus and substantive disclosure centers on Bellete's departure and associated severance benefits under his employment agreement. The departure of a C-suite officer (President \u0026 COO) is material to investors.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-05-27T02:10:23.327129+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":1482,"accession_number":"0001193125-26-237908","item_number":"5.02","item_title":"Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.","event_type":"exec_departure","event_domain":"governance","is_material":true,"confidence":0.75,"reasoning":"The filing discloses the separation of Ambaw Bellete, President \u0026 Chief Operating Officer, effective June 30, 2026. While the section also mentions Arthur Kuan's appointment as President, the primary focus and substantive disclosure centers on Bellete's departure and associated severance benefits under his employment agreement. The departure of a C-suite officer (President \u0026 COO) is material to investors.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-05-27T02:10:23.327129+00:00","company_name":"CG Oncology, Inc.","ticker":"CGON","filing_date":"2026-05-26"}]}